Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico

Cervantes-Luévano, Karla; Espino-Vazquez, Astrid N.; Flores-Acosta, Gonzalo; Bernáldez-Sarabia, Johanna; Cabanillas-Bernal, Olivia; Gasperin-Bulbarela, Jahaziel; González-Sánchez, Ricardo; Comas‐García, Andreu; Licea-Navarro, Alexei F.

doi:10.1371/journal.pone.0269032

Cited by 6 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mild decrease in antibody level was observed from first to seventh month in the Bologna cohort, with an overall persistence of vaccine-induced immunization. These results are consistent with previous findings from the ORCHESTRA study, including a partially overlapping set of cohorts [15,16], and corroborate previous literature on the topic [17][18][19][20].…”

Section: Discussionsupporting

confidence: 93%

Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

Collatuzzo

Lodi

Feola

et al. 2022

Viruses

View full text Add to dashboard Cite

Background: The persistence of antibody levels after COVID-19 vaccination has public health relevance. We analyzed the determinants of quantitative serology at 9 months after vaccination in a multicenter cohort. Methods: We analyzed data on anti-SARS-CoV-2 spike antibody levels at 9 months from the first dose of vaccinated HCW from eight centers in Italy, Germany, Spain, Romania and Slovakia. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of one standard deviation of log antibody level and the corresponding 95% confidence interval (CI), and combined them in random-effects meta-analyses. Finally, we conducted a trend analysis of 1 to 7 months’ serology within one cohort. Results: We included 20,216 HCW with up to two vaccine doses and showed that high antibody levels were associated with female sex (p = 0.01), age (RR = 0.87, 95% CI = 0.86–0.88 per 10-year increase), 10-day increase in time since last vaccine (RR = 0.97, 95% CI 0.97–0.98), previous infection (3.03, 95% CI = 2.92–3.13), two vaccine doses (RR = 1.22, 95% CI = 1.09–1.36), use of Spikevax (OR = 1.51, 95% CI = 1.39–1.64), Vaxzevria (OR = 0.57, 95% CI = 0.44–0.73) or heterologous vaccination (OR = 1.33, 95% CI = 1.12–1.57), compared to Comirnaty. The trend in the Bologna cohort, based on 3979 measurements, showed a decrease in mean standardized antibody level from 8.17 to 7.06 (1–7 months, p for trend 0.005). Conclusions: Our findings corroborate current knowledge on the determinants of COVID-19 vaccine-induced immunity and declining trend with time.

show abstract

Section: Discussionsupporting

confidence: 93%

Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

Collatuzzo

Lodi

Feola

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…No clear consistent effect of pre-existing immunity was observed, aligning with the clinical data from homologous Ad26 or ChAdOx1 regimens showing consistent boosting after the second dose [ 16 , 17 , 53 – 58 ]. In addition, spike-expressing adenovirus-based vector vaccines Ad26.COV2.S and Ad5-nCoV have shown to elicit similar levels of neutralizing antibodies in humans [ 59 ].…”

Section: Discussionmentioning

confidence: 99%

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses

Marquez-Martinez,

Salisch,

Serroyen

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Non-replicating adenovirus-based vectors have been broadly used for the development of prophylactic vaccines in humans and are licensed for COVID-19 and Ebola virus disease prevention. Adenovirus-based vectored vaccines encode for one or more disease specific transgenes with the aim to induce protective immunity against the target disease. The magnitude and duration of transgene expression of adenovirus 5- based vectors (human type C) in the host are key factors influencing antigen presentation and adaptive immune responses. Here we characterize the magnitude, duration, and organ biodistribution of transgene expression after single intramuscular administration of adenovirus 26-based vector vaccines in mice and evaluate the differences with adenovirus 5-based vector vaccine to understand if this is universally applicable across serotypes. We demonstrate a correlation between peak transgene expression early after adenovirus 26-based vaccination and transgene-specific cellular and humoral immune responses for a model antigen and SARS-CoV-2 spike protein, independent of innate immune activation. Notably, the memory immune response was similar in mice immunized with adenovirus 26-based vaccine and adenovirus 5-based vaccine, despite the latter inducing a higher peak of transgene expression early after immunization and a longer duration of transgene expression. Together these results provide further insights into the mode of action of adenovirus 26-based vector vaccines.

show abstract

“…The data obtained for immune escape across the variants in our study also correlated with another study on neutralization assay on individuals having first and second-dose COVID-19 vaccines ( 33 ). Besides, the heterologous vaccination (mixing) strategy is shown to increase neutralization levels with in vitro assays ( 30 , 34 ). These results show that our assay had the advantage of a high-throughput approach to obtain comprehensive data including both aspects.…”

Section: Discussionmentioning

confidence: 99%

Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays

Kuo¹,

Kuo²,

Du³

et al. 2023

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico

Cited by 6 publications

References 37 publications

Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses

Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays

Contact Info

Product

Resources

About